# Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

> **NCT02446652** · PHASE3 · WITHDRAWN · sponsor: **National Institute of Cancerología**

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Hydralazine/Magnesium
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02446652
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01-01
- **Primary completion:** 2018-07
- **Final completion:** 2018-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to a lack of sufficient resources, the opening was not carried out.
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446652, "Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02446652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*